Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune disease. It develops BT-11, a small molecule that targets a novel immunometabolic pathway within the gastrointestinal tract providing treatment and improved patient tolerability profile for such diseases as ulcerative colitis, Crohn’s disease, and others.